Aguirre LE, et al. Updates in risk stratification in myelodysplastic syndromes. Cancer J 2023;29(3):138-42. Abstract
Atluri H et al. Phase 1b/2 study of oral decitabine/cedazuridine (ASTX727) and venetoclax in combination with the targeted mutant IDH1 inhibitor ivosidenib or the targeted mutant IDH2 inhibitor enasidenib: 2023 update. ASH 2023;Abstract 968.
Daver NG et al. Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: Phase Ib results. J Clin Oncol 2023;41(31):4893-904. Abstract
Daver NG et al. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia: Phase 1b results. EHA 2022;Abstract S132.
De Botton S et al. Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to the placebo + azacitidine. ASCO 2023;Abstract 7012.
Erba HP et al. Quantum-First: Safety by treatment phase and by age in newly diagnosed (nd) patients (pts) with FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) positive acute myeloid leukemia (AML). ASH 2023;Abstract 972.
Erba HP et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): A randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;401(10388):1571-83. Abstract
Frumm SM et al. Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS. Blood Rev 2023;60:101056. Abstract
Garcia JS et al. Efficacy and safety of venetoclax in combination with azacitidine for the treatment of patients with treatment-naïve, higher-risk myelodysplastic syndromes. ASH 2023;Abstract 319.
Garcia-Manero G et al. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent (ESA)-naive patients (pts) with transfusion-dependent (TD) lower-risk myelodysplastic syndromes (LR-MDS): Full analysis of the COMMANDS trial. ASH 2023;Abstract 193.
Garcia-Manero G et al. ASTX727-03: Phase 1 study evaluating oral decitabine/cedazuridine (ASTX727) low-dose (LD) in lower-risk myelodysplastic syndromes (LR-MDS) patients. ASH 2022;Abstract 461.
Garcia-Manero G et al. Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): The phase 3, randomized, ENHANCE study. ASCO 2021;Abstract TPS7055.
Garciaz S et al. Acute myeloid leukemia patients who stopped venetoclax or/and azacytidine for other reasons than progression have a prolonged treatment free remission and overall survival. A Filo study. ASH 2023;Abstract 161.
Geissler K et al. Pharmacokinetic exposure equivalence and preliminary efficacy and safety from a randomized cross over phase 3 study of an oral hypomethylating agent DEC-C compared to IV decitabine in AML patients. EHA 2022;Abstract P573.
Komrokji RS et al. Efficacy of imetelstat in achieving red blood cell transfusion independence (RBC-TI) across different risk subgroups in patients with lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis-stimulating agents (ESAs) in IMerge phase 3 study. ASH 2023;Abstract 194.
Perl A et al. Quantum-First Trial: FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)-specific measurable residual disease (MRD) clearance assessed through induction (IND) and consolidation (CONS) is associated with improved overall survival (OS) in newly diagnosed (nd) FLT3-ITD+ AML patients (pts). ASH 2023;Abstract 832.
Pratz KW et al. Long-term follow-up of the phase 3 VIALE-A clinical trial of venetoclax plus azacitidine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. ASH 2022;Abstract 219.
Sallman DA et al. Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: Final results of a phase Ib study. J Clin Oncol 2023;41(15):2815-26. Abstract
Sallman DA et al. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results. ASCO 2020;Abstract 7507.
Shimony S et al. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 2023;98(3):502-26. Abstract
Suo X et al. Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: Updated results of a phase II trial. ASH 2023;Abstract 969.
Wei AH et al. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy. Blood 2022;140(25):2754-6. Abstract
Yilmaz M et al. Phase I/II study of quizartinib, venetoclax, and decitabine triple combination in FLT3-ITD mutated AML. ASH 2023;Abstract 158.